Literature DB >> 11353652

Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae.

D C Richardson1, D Bast, A McGeer, D E Low.   

Abstract

To determine if susceptibility testing of Streptococcus pneumoniae could detect those isolates that had one of the recognized mechanisms of fluoroquinolone resistance, 101 isolates were selected; the levofloxacin MIC for 28 of these isolates was > or =4 microg/ml. Only isolates with both parC and gyrA mutations or with no recognized resistance mechanisms were reliably identified by using these results. Isolates with only a parC mutation could not be detected reliably using any susceptibility testing method.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11353652      PMCID: PMC90572          DOI: 10.1128/AAC.45.6.1911-1914.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

2.  Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.

Authors:  X S Pan; J Ambler; S Mehtar; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

3.  Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.

Authors:  X S Pan; L M Fisher
Journal:  J Bacteriol       Date:  1996-07       Impact factor: 3.490

4.  Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.

Authors:  E Pestova; J J Millichap; G A Noskin; L R Peterson
Journal:  J Antimicrob Chemother       Date:  2000-05       Impact factor: 5.790

5.  Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis.

Authors:  B Fournier; X Zhao; T Lu; K Drlica; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

6.  Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.

Authors:  J Tankovic; B Perichon; J Duval; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

7.  Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.

Authors:  D J Bast; D E Low; C L Duncan; L Kilburn; L A Mandell; R J Davidson; J C de Azavedo
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

8.  Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.

Authors:  N P Brenwald; M J Gill; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

9.  THE SPECIFIC POLYSACCHARIDE CONTENT OF PNEUMONIC LUNGS.

Authors:  A W Frisch; J T Tripp; C D Barrett; B E Pidgeon
Journal:  J Exp Med       Date:  1942-12-01       Impact factor: 14.307

10.  Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.

Authors:  J H Jorgensen; L M Weigel; M J Ferraro; J M Swenson; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

View more
  11 in total

1.  Invasive Streptococcus pneumoniae in France: antimicrobial resistance, serotype, and molecular epidemiology findings from a monthly national study in 2000 to 2002.

Authors:  Jean-Winoc Decousser; Patrick Pina; Florent Viguier; Franc Picot; Patrice Courvalin; Pierre Allouch
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

2.  New real-time PCR assay using locked nucleic acid probes to assess prevalence of ParC mutations in fluoroquinolone-susceptible Streptococcus pneumoniae isolates from France.

Authors:  Jean-Winoc Decousser; Imen Methlouthi; Patrick Pina; Anne Collignon; Pierre Allouch
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

3.  Antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates in Portugal over an 11-year period.

Authors:  Ricardo Dias; Deolinda Louro; Manuela Caniça
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae.

Authors:  Emmanuelle Varon; Serge Houssaye; Sophie Grondin; Laurent Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 5.  Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?

Authors:  M Balter; K Weiss
Journal:  Can Fam Physician       Date:  2006-10       Impact factor: 3.275

6.  Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000.

Authors:  Donald E Low; Joyce de Azavedo; Karl Weiss; Tony Mazzulli; Magdalena Kuhn; Deirdre Church; Kevin Forward; George Zhanel; Andrew Simor; A McGeer
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

7.  Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

Authors:  Angela B Brueggemann; Stacy L Coffman; Paul Rhomberg; Holly Huynh; Laurel Almer; Angela Nilius; Robert Flamm; Gary V Doern
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

8.  In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002.

Authors:  Jeff Powis; Allison McGeer; Karen Green; Otto Vanderkooi; Karl Weiss; George Zhanel; Tony Mazzulli; Magdalena Kuhn; Deirdre Church; Ross Davidson; Kevin Forward; Daryl Hoban; Andrew Simor; Donald E Low
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.

Authors:  George P Allen; Glenn W Kaatz; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

Review 10.  Maintaining fluoroquinolone class efficacy: review of influencing factors.

Authors:  W Michael Scheld
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.